TY - JOUR
T1 - Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology
T2 - perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology
AU - Ketelhuth, Daniel F. J.
AU - Lutgens, Esther
AU - Bäck, Magnus
AU - Binder, Christoph J.
AU - van den Bossche, Jan
AU - Daniel, Carolin
AU - Dumitriu, Ingrid E.
AU - Hoefer, Imo
AU - Libby, Peter
AU - O'Neill, Luke
AU - Weber, Christian
AU - Evans, Paul C.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Inflammation is an important driver of atherosclerosis, and the favourable outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial revealed the large potential of anti-inflammatory drugs for the treatment of cardiovascular disease, especially in patients with a pro-inflammatory constitution. However, the complex immune reactions driving inflammation in the vascular wall in response to an atherosclerotic microenvironment are still being unravelled. Novel insights into the cellular processes driving immunity and inflammation revealed that alterations in intracellular metabolic pathways are strong drivers of survival, growth, and function of immune cells. Therefore, this position paper presents a brief overview of the recent developments in the immunometabolism field, focusing on its role in atherosclerosis. We will also highlight the potential impact of immunometabolic markers and targets in clinical cardiovascular medicine.
AB - Inflammation is an important driver of atherosclerosis, and the favourable outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial revealed the large potential of anti-inflammatory drugs for the treatment of cardiovascular disease, especially in patients with a pro-inflammatory constitution. However, the complex immune reactions driving inflammation in the vascular wall in response to an atherosclerotic microenvironment are still being unravelled. Novel insights into the cellular processes driving immunity and inflammation revealed that alterations in intracellular metabolic pathways are strong drivers of survival, growth, and function of immune cells. Therefore, this position paper presents a brief overview of the recent developments in the immunometabolism field, focusing on its role in atherosclerosis. We will also highlight the potential impact of immunometabolic markers and targets in clinical cardiovascular medicine.
KW - Immune system
KW - Inflammation
KW - Metabolism
KW - Vascular
KW - Atherosclerosis
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069270421&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31228191
UR - http://www.scopus.com/inward/record.url?scp=85069270421&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/cvr/cvz166
DO - https://doi.org/10.1093/cvr/cvz166
M3 - Article
C2 - 31228191
SN - 0008-6363
VL - 115
SP - 1385
EP - 1392
JO - Cardiovascular research
JF - Cardiovascular research
IS - 9
ER -